Tenaya Therapeutics has been granted a patent for compounds that inhibit HDAC6 activity, potentially treating various diseases. The formula for the compound is provided in the claim. GlobalData’s report on Tenaya Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Tenaya Therapeutics, Recombinant AAV gene therapy was a key innovation area identified from patents. Tenaya Therapeutics's grant share as of April 2024 was 7%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent (Publication Number: US11926622B2) discloses a compound with a specific chemical formula, as outlined in the claims. The compound includes various substituents and functional groups, such as alkyl, cycloalkyl, and heteroaryl, which contribute to its structure and properties. Additionally, the patent describes different configurations and arrangements of the compound, including the presence of phenyl groups that may be substituted with halogen, alkyl, or other moieties.
Furthermore, the patent details the formation of heterocyclic structures within the compound, along with the possible substitutions and variations that can occur. The claims also specify the presence of certain atoms and groups, such as oxygen or methylene bridges, which further define the compound's structure. Overall, the patent provides a comprehensive overview of the compound's chemical composition and structural characteristics, offering valuable insights for researchers and professionals in the field of chemistry and pharmaceuticals.
To know more about GlobalData’s detailed insights on Tenaya Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.